SAN DIEGO, September 27, 2018 – ProSciento, Inc., a leading specialty clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases, will present clinical research data at the 54th European Association for the Study of Diabetes (EASD) Annual Meeting, October 1-5 in Berlin.
Poster presentations co-authored by ProSciento scientists include:
- MEDI4166, a novel antibody-peptide fusion molecule: multiple-ascending-dose study in patients with type 2 diabetes (Abstract #166)
Session: Novel drug therapies: Moving beyond GLP1 - Impact of praliciguat, a soluble guanylate cyclase stimulator, on blood pressure and metabolic parameters in patients with diabetes and hypertension (Abstract #167)
Session: Novel drug therapies: Moving beyond GLP1 - Preclinical effects of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist, compared with liraglutide and dulaglutide (Abstract #712)
Session: Metabolic effects of novel, dual and triple incretin agonists - Investigations into tissue distribution and inhibition of food consumption with efpeglenatide (Abstract #716)
Session: Metabolic effects of novel, dual and triple incretin agonists - The effect of efpeglenatide on lipid profiles and overall metabolism in patients with type 2 diabetes and obese patients without diabetes (Abstract #723)
Session: Lipids and fatty liver: What GLP1 receptor agonists can do - In vitro studies to evaluate the receptor kinetics of efpeglenatide versus other glucagon-like peptide-1 receptor agonists (Abstract #790)
Session: Beta cell function and response to incretin-based therapies
About ProSciento, Inc.
ProSciento is a leading specialty clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases. ProSciento works with biopharma companies worldwide to support their outsourced clinical research needs with comprehensive and customized services for multinational, early development clinical trial programs. Founded in 2003, ProSciento has conducted more than 280 clinical projects for diabetes, NASH and obesity and supported the development of many approved metabolic drugs and devices on the market globally today.
For media inquiries, please contact:
Abby Devine
Senior Director, Corporate Communications, ProSciento, Inc.
abby.devine@prosciento.com
For business development inquires:
bd@prosciento.com
For clinical study enrollment inquiries:
Tel: +1 (866) 308-7427
volunteer@prosciento.com
